

Bpl Wijnhoven

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11852849/publications.pdf>

Version: 2024-02-01

14
papers

4,593
citations

1040056

9
h-index

1199594

12
g-index

14
all docs

14
docs citations

14
times ranked

4989
citing authors

#	ARTICLE	IF	CITATIONS
1	Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2074-2084.	27.0	4,296
2	Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study. <i>Annals of Oncology</i> , 2017, 28, 519-527.	1.2	65
3	Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial. <i>Annals of Oncology</i> , 2018, 29, 445-451.	1.2	50
4	Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study. <i>European Journal of Cancer</i> , 2018, 91, 76-85.	2.8	39
5	Cancer stem cells and their potential implications for the treatment of solid tumors. <i>Journal of Surgical Oncology</i> , 2012, 106, 209-215.	1.7	36
6	Management of resectable esophageal and gastric (mixed adeno)neuroendocrine carcinoma: A nationwide cohort study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1955-1962.	1.0	29
7	A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy. <i>European Journal of Surgical Oncology</i> , 2019, 45, 931-940.	1.0	27
8	Role of Chemoradiotherapy in Oesophageal Cancer – Adjuvant and Neoadjuvant Therapy. <i>Clinical Oncology</i> , 2014, 26, 522-532.	1.4	17
9	Neoadjuvant chemoradiotherapy for resectable oesophageal cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 36-37, 37-44.	2.4	15
10	Tumor microRNA-126 controls cell viability and associates with poor survival in patients with esophageal adenocarcinoma. <i>Experimental Biology and Medicine</i> , 2019, 244, 1210-1219.	2.4	8
11	Absence of TERT promoter mutations in esophageal adenocarcinoma. <i>International Journal of Cancer</i> , 2014, 134, 2014-2015.	5.1	5
12	Induction chemotherapy followed by surgery for advanced oesophageal cancer. <i>European Journal of Surgical Oncology</i> , 2015, 41, 323-332.	1.0	5
13	Surgical Approaches to Remove the Esophagus. , 2019, , 405-414.		1
14	INDIVIDUAL RISK CALCULATOR TO PREDICT LYMPH NODE METASTASES IN PATIENTS WITH SUBMUCOSAL (T1B) ESOPHAGEAL ADENOCARCINOMA: MULTICENTER COHORT STUDY. , 2020, 52, .		0